Stock Analysis on Net

Thermo Fisher Scientific Inc. (NYSE:TMO)

$24.99

Current Ratio
since 2005

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Thermo Fisher Scientific Inc., current ratio, long-term trends, calculation

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$ in millions


The current ratio exhibited considerable fluctuation between 2005 and 2025. Initially, the ratio remained relatively stable, hovering around 1.70 from 2005 to 2007. A significant increase was then observed, peaking at 2.82 in 2008, before declining to 2.42 in 2010. The period from 2011 to 2015 saw a marked decrease, reaching a low of 1.22 in 2013. A subsequent recovery occurred, with the ratio rising to 1.44 by 2015. Further increases followed, reaching 1.92 in 2019, before a decline to 1.50 in 2021. The ratio experienced a slight increase to 1.48 in 2022, followed by a rise to 1.75 in 2023 and 1.89 in 2025.

Overall Trend
The overall trend demonstrates cyclical behavior. Periods of growth in the current ratio were often followed by periods of decline. While the ratio generally remained above 1.0, indicating sufficient current assets to cover current liabilities, the substantial fluctuations suggest potential shifts in working capital management or short-term financial strategies.
Significant Increases
The most notable increase occurred between 2007 and 2008, potentially reflecting a strategic accumulation of current assets or a reduction in current liabilities. The increase from 2013 to 2015 could be attributed to improved liquidity management or a change in the composition of current assets and liabilities.
Significant Decreases
The decline from 2008 to 2010 and the more pronounced drop from 2011 to 2013 warrant further investigation. These decreases could indicate increased reliance on short-term financing, a decrease in the liquidity of current assets, or a rise in current liabilities. The dip in 2021 may be related to increased short-term obligations or investment in current assets.
Recent Performance (2020-2025)
From 2020 to 2025, the current ratio experienced moderate fluctuations. The ratio decreased from 2.13 in 2020 to 1.50 in 2021, then showed a slight recovery to 1.89 in 2025. This suggests a stabilization of liquidity position, although continued monitoring is advisable.

In conclusion, the current ratio demonstrates a dynamic pattern over the analyzed period. While generally indicating a healthy liquidity position, the observed fluctuations highlight the importance of ongoing monitoring and analysis of underlying working capital components.


Comparison to Competitors

Thermo Fisher Scientific Inc., current ratio, long-term trends, comparison to competitors

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

Thermo Fisher Scientific Inc., current ratio, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Industry (Health Care)